Fresenius SE & Co KGaA (FRE) PT Set at €59.00 by UBS Group
Fresenius SE & Co KGaA (FRA:FRE) has been given a €59.00 ($70.24) price objective by equities research analysts at UBS Group in a report released on Friday, www.boersen-zeitung.de reports. The brokerage presently has a “sell” rating on the stock. UBS Group’s price objective suggests a potential downside of 11.97% from the stock’s current price.
Several other brokerages have also recently commented on FRE. Citigroup set a €83.00 ($98.81) price target on shares of Fresenius SE & Co KGaA and gave the stock a “buy” rating in a research report on Thursday, October 19th. Goldman Sachs Group set a €78.00 ($92.86) price target on shares of Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a research report on Tuesday, October 31st. Warburg Research set a €80.00 ($95.24) price target on shares of Fresenius SE & Co KGaA and gave the stock a “buy” rating in a research report on Thursday, December 21st. Bank of America set a €75.00 ($89.29) price target on shares of Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a research report on Monday, November 6th. Finally, Kepler Capital Markets set a €63.00 ($75.00) target price on shares of Fresenius SE & Co KGaA and gave the company a “neutral” rating in a report on Tuesday, November 28th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and eleven have given a buy rating to the company. Fresenius SE & Co KGaA has a consensus rating of “Buy” and an average target price of €78.66 ($93.65).
Shares of Fresenius SE & Co KGaA (FRE) traded up €1.36 ($1.62) during trading hours on Friday, reaching €67.02 ($79.79). 10,158 shares of the company’s stock traded hands. Fresenius SE & Co KGaA has a 52-week low of €60.16 ($71.62) and a 52-week high of €80.00 ($95.24). The company has a market cap of $37,040.00 and a PE ratio of 21.34.
COPYRIGHT VIOLATION WARNING: This news story was first published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/05/fresenius-se-59-00-by-ubs-group.html.
Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.
Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.